Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2022-06-21 Regulatory Filings
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
SUPPLEMENTAL ANNOUNCEMENT - RENEWAL OF CONTINUING CONNECTED TRANSACTIONS
Regulatory Filings Classification · 95% confidence The document is titled as a "Supplemental Announcement" related to the renewal of continuing connected transactions for RemeGen Co., Ltd. It references a prior announcement dated May 24, 2022, and provides additional details on pricing policies and internal control procedures for various service agreements. The content is focused on disclosure of transaction terms and compliance with listing rules, typical of regulatory announcements. There are no financial statements, earnings data, or management discussion of financial results. The document is an announcement supplementing a previous disclosure rather than a full report or financial filing. It fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-06-21 English
Monthly Return of Equity Issuer on Movement in Securities for the month ended 31 May 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return report detailing movements in securities, specifically authorized and issued shares, for Overseas Chinese Town (Asia) Holdings Limited. It includes confirmations related to share capital and securities issued, with no financial statements or earnings data. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share issuance movements for the month ended 31 May 2022. It does not contain financial results, management discussion, or audit information. This type of document fits the category of a Regulatory Filing (RNS) as it is a compliance report on share capital movements and confirmations, not a financial report or announcement of a report publication.
2022-06-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return detailing movements in securities, specifically focusing on authorized and issued share capital, share options, convertibles, and confirmations related to securities issued by the company. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with listing rules. The content is regulatory in nature, reporting share capital and share issuance movements, but does not contain financial statements or detailed financial performance data. It is not an announcement of a report publication but a regulatory filing of share capital movements and confirmations. Therefore, it fits best under Regulatory Filings (RNS).
2022-06-06 English
DISCLOSEABLE TRANSACTION - PURCHASE OF WEALTH MANAGEMENT PRODUCTS
Capital/Financing Update Classification · 95% confidence The document is an announcement by RemeGen Co., Ltd. regarding the purchase of wealth management products using idle raised proceeds from an A Share Offering. It details multiple agreements with Qingdao Bank for structured deposit products, including terms, amounts, and dates. The document references Listing Rules and discloses the nature of the transactions as discloseable transactions under Chapter 14 of the Listing Rules, subject to reporting and announcement requirements but exempt from shareholders' approval. The content is focused on a capital/financing update related to the company's use of raised proceeds and investment in financial products. It is not a full financial report, earnings release, or management discussion, nor is it a regulatory filing or announcement of a report publication. The document is substantive and detailed, exceeding 5,000 characters, and is clearly an update on financing activities. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-05-31 English
2021 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information Classification · 100% confidence The document is titled '2021 Environmental, Social and Governance Report' for RemeGen Co., Ltd. It covers ESG topics such as sustainability, safety, environmental protection, employee and community engagement, and governance related to ESG. The report states it is the second ESG report released by the company and covers the full year 2021. It references ESG reporting guidelines from the Hong Kong Stock Exchange and the Global Reporting Initiative. The content is focused on environmental, social, and governance performance rather than financial results or corporate governance structure alone. There is no indication that this is an annual financial report, audit report, or earnings release. The document is a comprehensive ESG report, fitting the definition of Environmental & Social Information (SR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement or summary.
2022-05-31 English
Notification Letter and Request Form to Non-Registered Holders - Notice of Publication of Annual General Meeting Circular ("Current Corporate Communications")
Report Publication Announcement Classification · 95% confidence The document is a notification letter dated 31 May 2022 from RemeGen Co., Ltd. addressed to non-registered shareholders. It informs recipients about the publication of the Annual General Meeting (AGM) Circular and provides instructions on how to access the circular electronically or request a printed version. The document includes a request form for shareholders to specify their preferred format for receiving corporate communications. The content focuses on the announcement of the availability of the AGM circular rather than the AGM materials themselves. The document length is 6820 characters, which is relatively short and consistent with an announcement or notification rather than a full report. There is no detailed financial data, management discussion, or meeting minutes included. Therefore, this document is best classified as a Report Publication Announcement (RPA) because it announces the publication of the AGM circular and provides instructions for shareholders to obtain it, rather than containing the AGM materials themselves.
2022-05-30 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.